345 related articles for article (PubMed ID: 19019888)
1. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.
Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J
Ann Rheum Dis; 2009 Oct; 68(10):1580-4. PubMed ID: 19019888
[TBL] [Abstract][Full Text] [Related]
2. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
Burmester GR; Feist E; Kellner H; Braun J; Iking-Konert C; Rubbert-Roth A
Ann Rheum Dis; 2011 May; 70(5):755-9. PubMed ID: 21187298
[TBL] [Abstract][Full Text] [Related]
5. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
[TBL] [Abstract][Full Text] [Related]
6. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
Bykerk VP; Östör AJK; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Nurmohamed MT; Luder Y; Sidiropoulos PNM; Devenport J; Sibilia J
Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice.
Bouajina E; Zakraoui L; Kchir M; Kochbati S; Baklouti S
Clin Rheumatol; 2020 May; 39(5):1449-1455. PubMed ID: 31838637
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
Kivitz A; Olech E; Borofsky M; Zazueta BM; Navarro-Sarabia F; Radominski SC; Merrill JT; Rowell L; Nasmyth-Miller C; Bao M; Wright S; Pope JE
Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1653-61. PubMed ID: 24942540
[TBL] [Abstract][Full Text] [Related]
10. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials.
An MM; Zou Z; Shen H; Zhang JD; Cao YB; Jiang YY
Eur J Clin Pharmacol; 2010 Jan; 66(1):49-59. PubMed ID: 19936725
[TBL] [Abstract][Full Text] [Related]
11. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
Emery P; Keystone E; Tony HP; Cantagrel A; van Vollenhoven R; Sanchez A; Alecock E; Lee J; Kremer J
Ann Rheum Dis; 2008 Nov; 67(11):1516-23. PubMed ID: 18625622
[TBL] [Abstract][Full Text] [Related]
12. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.
Jones G; Sebba A; Gu J; Lowenstein MB; Calvo A; Gomez-Reino JJ; Siri DA; Tomsic M; Alecock E; Woodworth T; Genovese MC
Ann Rheum Dis; 2010 Jan; 69(1):88-96. PubMed ID: 19297346
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions.
Nishimoto N; Ito K; Takagi N
Mod Rheumatol; 2010 Jun; 20(3):222-32. PubMed ID: 20221663
[TBL] [Abstract][Full Text] [Related]
14. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).
Yamanaka H; Tanaka Y; Inoue E; Hoshi D; Momohara S; Hanami K; Yunoue N; Saito K; Amano K; Kameda H; Takeuchi T
Mod Rheumatol; 2011 Apr; 21(2):122-33. PubMed ID: 20953815
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J
Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
18. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML; Haavardsholm EA; Rudin A; Nordström D; Nurmohamed M; Gudbjornsson B; Lampa J; Hørslev-Petersen K; Uhlig T; Grondal G; Østergaard M; Heiberg MS; Twisk J; Lend K; Krabbe S; Hyldstrup LH; Lindqvist J; Hultgård Ekwall AK; Grøn KL; Kapetanovic M; Faustini F; Tuompo R; Lorenzen T; Cagnotto G; Baecklund E; Hendricks O; Vedder D; Sokka-Isler T; Husmark T; Ljoså MA; Brodin E; Ellingsen T; Söderbergh A; Rizk M; Olsson ÅR; Larsson P; Uhrenholt L; Just SA; Stevens DJ; Laurberg TB; Bakland G; Olsen IC; van Vollenhoven R;
BMJ; 2020 Dec; 371():m4328. PubMed ID: 33268527
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis.
Baek HJ; Lim MJ; Park W; Park SH; Shim SC; Yoo DH; Kim HA; Lee SK; Lee YJ; Park YE; Cha HS; Song YW
Korean J Intern Med; 2019 Jul; 34(4):917-931. PubMed ID: 29334721
[TBL] [Abstract][Full Text] [Related]
20. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
Genovese MC; Rubbert-Roth A; Smolen JS; Kremer J; Khraishi M; Gómez-Reino J; Sebba A; Pilson R; Williams S; Van Vollenhoven R
J Rheumatol; 2013 Jun; 40(6):768-80. PubMed ID: 23457383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]